2649467-58-1
Chemical Structure
Suzetrigine
Synonym(s): VX-548
- CAS No.: 2649467-58-1
- Formula:C21H20F5N3O4
- Molecular Weight:473.39
IUPAC Name: 4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamido)picolinamide
InChIKey: XSQUJFKRXZMOKA-PAFIKIDNSA-N
SMILES: NC(C1=CC(NC([C@H]2[C@H](C3=C(C(F)=C(C=C3)F)OC)[C@@H]([C@@](C)(O2)C(F)(F)F)C)=O)=CC=N1)=O
Biological Activity: Suzetrigine (VX-548) is an orally active and highly selective NaV1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Suzetrigine | 99.98% | Suzetrigine (VX-548) is an orally active and highly selective NaV1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Suzetrigine (Standard) | ≥98% | Suzetrigine (Standard) is the analytical standard of Suzetrigine (HY-148800). This product is intended for research and analytical applications. Suzetrigine (VX-548) is an orally active and highly selective NaV1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jones J, et al. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405. [Content Brief]
- [2]. WHO Drug Information-World Health Organization (WHO).
- [3]. Zhang H, et al. A simple and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX-548 in monkey plasma: Method validation and application to pharmacokinetic study. Biomed Chromatogr. 2024 Jul;38(7):e5907. [Content Brief]
- [4]. Yu G, et al. Gender difference in the pharmacokinetics and metabolism of VX-548 in rats. Biopharm Drug Dispos. 2024 Apr;45(2):107-114. [Content Brief]
- [5]. Qin H, et al. Discovery of selective NaV1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain. Eur J Med Chem. 2023 Jun 5;254:115371. [Content Brief]
